CD274 and non-small cell lung carcinoma: Limited data exist about comparing prognostic outcomes among patients carrying EGFR‐mutated NSCLC with PD‐L1 TPS ≥20% and those with PD‐L1 TPS <20% up to date, although most previous research has compared outcomes using PD‐L1 TPS ≥50%, 50% > PD‐L1 TPS ≥1%, and PD‐L1 TPS <1% as a cut‐off.